AGC earnings date
Want to see JP:5201 full AI Analyst Report?
AGC (5201) Q3 2026 Earnings Report
JP:5201 Q3 2026 EPS Results
- Actual EPS
- -JPY 9.86
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- JPY 120.66
JP:5201 Q3 2026 Revenue Results
- Actual Revenue
- JPY 562.00B
- Expected Revenue
- JPY 569.28B
- Beat/Miss
- Missed by -JPY 7.28B
- YoY Revenue Growth
- +8.77%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- Before Open
- Conference Call
- Thursday, November 5, 2026
AGC's next earnings date is estimated for February 5, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call included meaningful positives, including higher sales, strong Chemicals and strategic business performance, positive free cash flow, recovery initiatives, and maintained shareholder returns. However, the overall tone was negative because operating profit and net income declined, full-year operating profit and net profit guidance were cut substantially, several major segments faced operational or market-related challenges, and management acknowledged repeated downward revisions and internal execution issues.
Full-year net sales remains unchanged at JPY 2.2 trillion, while operating profit has been revised downwards to JPY 120 billion, down JPY 30 billion, and net profit attributable to owners of the parent to JPY 40 billion, down JPY 37 billion; full-year FX assumptions are U.S. dollar to JPY 160 and euro to JPY 180. Operating profit revisions are JPY 1 billion for Chemicals, JPY 15 billion for Automotive, JPY 9 billion for Architectural Glass and JPY 8 billion for Life Sciences. Strategic-business net sales is revised down by JPY 10 billion to JPY 550 billion and operating profit revised upward by JPY 5 billion to JPY 85 billion. Q4 guidance includes increased shipments in Asia Architectural Glass, limited recovery in Europe, declining Automotive shipments, slightly slower glass LCD substrate shipments, increased semiconductor-related-material shipments, decreased Optoelectronic-material shipments, declining fluoropolymer shipments, increased caustic soda shipments, decreased PVC shipments, and profits expected to improve, but remain at low level. CapEx is expected to increase by JPY 15 billion to JPY 205 billion, depreciation will be JPY 195 billion, up JPY 12 billion, and the planned year-end dividend remains unchanged at JPY 105 per share under a stable dividend policy targeting DOE of approximately 3%.
- Cumulative Net Sales GrowthYear-on-year net sales increased by JPY 105.5 billion. Third-quarter sales were JPY 1,662.6 billion, up JPY 150.5 billion, supported by a weaker yen, higher shipments of chemicals and electronic materials, and pricing policies in Integrated Chemicals and Architectural Glass Europe.
- Chemicals Segment GrowthChemicals net sales increased by JPY 84.4 billion to JPY 515.7 billion, while operating profit increased by JPY 41 billion to JPY 43.7 billion. Integrated Chemicals benefited from higher sales prices and increased shipments for semiconductor and other electronics, while Essential Chemicals Southeast Asia benefited from increased shipments following capacity enhancement in Thailand.
- Strong Electronic Materials DemandElectronic Materials sales increased due to higher shipments of semiconductor-related materials, including EUV photomask blanks and optoelectronics, as well as the benefit of a weaker yen. Semiconductor-related demand remained robust for EUV mask blanks and CMP slurry.
- Strategic Businesses Delivered Significant GrowthStrategic business net sales increased by JPY 39.5 billion year-on-year to JPY 40.8 billion, and operating profit increased by JPY 16.9 billion to JPY 57.6 billion. Growth in Performance Chemicals and Electronics contributed to the increase in profit, and strategic businesses accounted for 62% of total group operating profit.
- Life Science Profitability Improved Year-on-YearLife Science operating loss improved by JPY 3.6 billion year-on-year, although the segment remained loss-making. The improvement was attributed to reduced fixed costs, including the closure of the biopharmaceutical CDMO site in Colorado.
- Positive Free Cash Flow and LeverageOperating cash flow was positive JPY 150.1 billion and investing cash flow was negative JPY 120.8 billion, resulting in positive free cash flow of JPY 29.3 billion. The debt-to-equity ratio was 0.40.
- Profitability Improvement and Structural MeasuresThe company implemented workforce optimization and other structural improvements in Architectural Glass, sold its European replacement glass installation business in Automotive, decided to end production at the Integrated Chemicals U.K. site by year-end, and completed the sale of the Colorado CDMO site except for part of the land.
- Strategic Business Operating Profit Forecast IncreasedAlthough strategic business net sales were revised down by JPY 10 billion to JPY 550 billion, operating profit was revised upward by JPY 5 billion to JPY 85 billion, driven by strong performance in Performance Chemicals and Electronics.
- Order Intake Showing Signs of Recovery in Life ScienceManagement said Life Science order intake was showing signs of recovery. New orders, especially for the Copenhagen site, were expected to increase in the fourth quarter, with October and November sales expected to be above the breakeven point for the bio business.
- Planned Automotive and Life Science Recovery ActionsThe company plans to strengthen manufacturing and technical management in Automotive, review the structure of its North American business, and improve manufacturing productivity. In Life Science, management aims to expand the order book, maintain stable production, and achieve at least breakeven or move into positive territory.
- Electronics Pricing and Product Functionality InitiativesThe company is continuing price increases for display products and plans to increase prices next year at about the same level as in the current fiscal year to cover costs and provide higher functionalities and features. For Optoelectronics, management expects improved profitability toward next fiscal year as the product mix shifts toward higher-functionality products.
- Capital Investment and R&D ProgramFor the first nine months, CapEx totaled JPY 139.8 billion, depreciation was JPY 147.4 billion, and R&D expenses were JPY 43 billion. Full-year CapEx is expected to increase by JPY 15 billion from the initial forecast to JPY 205 billion due to higher construction costs and a weaker yen, while R&D guidance remains unchanged.
- Dividend Policy MaintainedThe company made no change to its stable dividend policy targeting a DOE of approximately 3%. The planned year-end dividend remains unchanged at JPY 105 per share.
- Some Fourth-Quarter Volume and Market Improvements ExpectedArchitectural Glass shipments in Asia are expected to increase due to seasonal factors. Semiconductor-related material shipments are expected to increase, caustic soda shipments in Essential Chemicals Southeast Asia are expected to increase, and Life Science sales in small molecule pharmaceuticals, agrochemical CDMO, and biopharmaceutical CDMO are expected to rise due to seasonal factors and higher utilization at the Copenhagen site.
JP:5201 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 05, 2027 | 2026 (Q4) | ―- | 139.95 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | ―-9.86 | 120.66 | -108.17% (-130.52) | |
| Aug 04, 2026 | 2026 (Q2) | ―59.72 | 34.24 | 74.42% (+25.48) | |
| May 12, 2026 | 2026 (Q1) | ―107.73 | 31.35 | 243.64% (+76.38) | |
| Feb 06, 2026 | 2025 (Q4) | ―139.95 | 58.37 | 139.76% (+81.58) | |
| Nov 05, 2025 | 2025 (Q3) | ―120.66 | 38.18 | 216.03% (+82.48) | |
| Aug 01, 2025 | 2025 (Q2) | ―34.24 | -441.36 | 107.76% (+475.60) | |
| May 12, 2025 | 2025 (Q1) | ―31.35 | -98.9 | 131.70% (+130.25) | |
| Feb 07, 2025 | 2024 (Q4) | ―58.37 | 119.53 | -51.17% (-61.16) | |
| Nov 01, 2024 | 2024 (Q3) | ―38.18 | 79.76 | -52.13% (-41.58) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


